Zydus develops new treatment for patients suffering from Chronic Kidney Disease
November 23, 2021
Gandhinagar(Press release) Zydus Cadila, an innovation-driven, global pharmaceutical company, today announced that it has submitted the New Drug Application (NDA) to the Drug Controller General of India for Desidustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for treatment of anaemia in patients with Chronic Kidney Disease (CKD) who are on Dialysis and Not on Dialysis.
Chronic Kidney Disease is a serious progressive medical condition which is a global unmet healthcare need involving gradual loss of functioning of kidneys eventually leading to kidney failure. It has been reported that 114 million people in India, 132 million people in China, 38 million people in the United States, 21 million patients in Japan and 41 million people in Western Europe are estimated to be living with Chronic Kidney Disease (Lancet 2020; 395: 709–33).
Recent Stories
- National Highways in Gujarat where tolls are being charged; full nationwide list here
- New Hormonal Products Plant of CORONA Remedies to be operational in FY 2026
- AICFF, NBT collab to hold Children's Film Festival during Ahmedabad International Book Festival 2024
- Gujarat govt appoints IPS Neeraja Gotru as ADGP, Police Recruitment Board
- Ahmedabad SOG busts racket printing fake Australian dollar notes
- Indian Hotels Company signs a Gateway Resort in Kandla, Gujarat
- Deputy PM of Fiji pays courtesy visit to Gujarat CM in Gandhinagar